Australian NMD Registry Consent Form Version[removed]

First Page		Document Content
Date: 2015-02-25 01:48:04 Pharmaceutical industry Muscular dystrophy Clinical trial Design of experiments Pharmacology Disease registry Spinal muscular atrophy TREAT-NMD Duchenne muscular dystrophy Medicine Health Clinical research		Australian NMD Registry Consent Form Version[removed] Add to Reading List Source URL: nmdregistry.com.au Download Document from Source Website File Size: 443,53 KB Share Document on Facebook

	Mutations in BICD2 Cause Dominant Congenital Spinal Muscular Atrophy and Hereditary Spastic Paraplegia DocID: 1uWce - View Document
	Fostering Health and Growth for Spinal Muscular Atrophy SMA CARE SERIES Nutrition Basics DocID: 1trbw - View Document
	TRAINING IMPROVES OXIDATIVE CAPACITY, BUT NOT FUNCTION, IN SPINAL MUSCULAR ATROPHY TYPE III DocID: 1tqwe - View Document
	Resistance Strength Training Exercise in Children with Spinal Muscular Atrophy Aga Lewelt, MD, MS1; Kristin J. Krosschell, PT, DPT, MA, PCS2; Gregory J. Stoddard, MS3; Cindy Weng, MS3; Mei Xue, MS4; Robin L. Marcus, PT, DocID: 1tqop - View Document
	Dear Primary Care Provider, Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disease characterized by weakness of the skeletal and respiratory muscles. SMA is a rare disorder occurring approximately 1 in 10,000 b DocID: 1tkD5 - View Document